Selected article for: "fatigue headache and nausea vomiting"

Author: D, Vitalakumar; Sharma, Ankita; Kumar, Anoop; Flora, S. J. S.
Title: Neurological Manifestations in COVID-19 Patients: A Meta-Analysis
  • Cord-id: moxq6wrq
  • Document date: 2021_7_14
  • ID: moxq6wrq
    Snippet: [Image: see text] Common symptoms such as dizziness, headache, olfactory dysfunction, nausea, vomiting, etc. in COVID-19 patients have indicated the involvement of the nervous system. However, the exact association of the nervous system with COVID-19 infection is still unclear. Thus, we have conducted a meta-analysis of clinical studies associated with neurological problems in COVID-19 patients. We have searched for electronic databases with MeSH terms, and the studies for analysis were selected
    Document: [Image: see text] Common symptoms such as dizziness, headache, olfactory dysfunction, nausea, vomiting, etc. in COVID-19 patients have indicated the involvement of the nervous system. However, the exact association of the nervous system with COVID-19 infection is still unclear. Thus, we have conducted a meta-analysis of clinical studies associated with neurological problems in COVID-19 patients. We have searched for electronic databases with MeSH terms, and the studies for analysis were selected based on inclusion and exclusion criteria and quality assessment. The Stats Direct (version 3) was used for the analysis. The pooled prevalence with 95% confidence interval of various neurological manifestations reported in the COVID-19 patients was found to be headache 14.6% (12.2–17.2), fatigue 33.6% (29.5–37.8), olfactory dysfunction 26.4% (21.8–31.3), gustatory dysfunction 27.2% (22.3–32.3), vomiting 6.7% (5.5–8.0), nausea 9.8% (8.1–11.7), dizziness 6.7% (4.7–9.1), myalgia 21.4% (18.8–24.1), seizure 4.05% (2.5–5.8), cerebrovascular diseases 9.9% (6.8–13.4), sleep disorders 14.9% (1.9–36.8), altered mental status 17.1% (12.3–22.5), neuralgia 2.4% (0.8–4.7), arthralgia 19.9% (15.3–25.0), encephalopathy 23.5% (14.3–34.1), encephalitis 0.6% (0.2–1.3), malaise 38.3% (24.7–52.9), confusion 14.2% (6.9–23.5), movement disorders 5.2% (1.7–10.4), and Guillain–Barre syndrome 6.9% (2.3–13.7). However, the heterogeneity among studies was found to be high. Various neurological manifestations related to the central nervous system (CNS) and peripheral nervous system (PNS) are associated with COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abnormal coagulation and acute stroke: 1, 2
    • acute hemorrhage and lung alveolar: 1, 2, 3
    • acute hemorrhage and lung alveolar damage: 1
    • acute hemorrhage and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8
    • acute hemorrhagic necrotizing encephalopathy and magnetic resonance: 1
    • acute motor aman axonal neuropathy and magnetic resonance: 1
    • acute stroke and lung alveolar: 1, 2
    • acute stroke and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute stroke detection and magnetic resonance: 1
    • acute subacute and lung alveolar: 1, 2, 3
    • acute subacute and lung alveolar damage: 1
    • acute subacute and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lung alveolar and magnetic resonance: 1